What question did this study set out to answer?

To identify treatment regimens used after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.

December 8, 2025Blood

Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study

View Full Paper

Ask AI

Bookmark

Authors

Real-world study reveals common regimens post-CAR T in multiple myeloma, indicating treatment variations across countries.

To identify treatment regimens used after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Analyzed anonymous patient charts from onco-hematologists in the EU5, US, and Japan.
Included patients who received ide-cel or cilta-cel between 3rd and 5th lines of therapy.
Focused on primary combinations and regimens post-therapy.
91% of patients were in their 4th or 5th line of therapy.
52% were lenalidomide-refractory, indicating extensive prior treatment exposure.
Common treatments included elotuzumab and isatuximab-based regimens in the 3rd line; teclistamab-based options in the 4th and 5th lines.

Mai et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Real-world study reveals common regimens post-CAR T in multiple myeloma, indicating treatment variations across countries.

To identify treatment regimens used after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
Analyzed anonymous patient charts from onco-hematologists in the EU5, US, and Japan.
Included patients who received ide-cel or cilta-cel between 3rd and 5th lines of therapy.
Focused on primary combinations and regimens post-therapy.
91% of patients were in their 4th or 5th line of therapy.
52% were lenalidomide-refractory, indicating extensive prior treatment exposure.
Common treatments included elotuzumab and isatuximab-based regimens in the 3rd line; teclistamab-based options in the 4th and 5th lines.

Mai et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark